Keywords: Amyloid light-chain cardiac amyloidosis; Androgen deprivation therapy; Anthracycline; Arrhythmias; Atrial fibrillation; Biomarkers; Cancer; Cancer survivors; Carcinoid syndrome; Cardiac magnetic resonance; Cardiac tumour; Cardio-oncology; Cardiotoxicity; Chemotherapy; Coronary artery disease; Echocardiography; Fluoropyrimidine; Guidelines; Haematopoietic stem cell transplantation; Heart failure; Hormone therapy; Hypertension; Immunotherapy; Ischaemic heart disease; Myocarditis; Pericardial disease; Proteasome inhibitors; Pulmonary hypertension; QTc prolongation; Radiotherapy; Risk stratification; Strain; Thrombosis; Trastuzumab; Valvular heart disease; Vascular endothelial growth factor inhibitors (VEGFi); Venous thromboembolism.